Ocular Therapeutix (OCUL) Income towards Parent Company: 2013-2025
Historic Income towards Parent Company for Ocular Therapeutix (OCUL) over the last 13 years, with Sep 2025 value amounting to -$68.0 million.
- Ocular Therapeutix's Income towards Parent Company fell 56.01% to -$68.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$247.3 million, marking a year-over-year decrease of 78.13%. This contributed to the annual value of -$165.1 million for FY2024, which is 83.96% down from last year.
- Per Ocular Therapeutix's latest filing, its Income towards Parent Company stood at -$68.0 million for Q3 2025, which was down 1.14% from -$67.2 million recorded in Q2 2025.
- In the past 5 years, Ocular Therapeutix's Income towards Parent Company ranged from a high of -$19.5 million in Q1 2022 and a low of -$68.0 million during Q3 2025.
- Moreover, its 3-year median value for Income towards Parent Company was -$40.8 million (2024), whereas its average is -$41.2 million.
- In the last 5 years, Ocular Therapeutix's Income towards Parent Company climbed by 10.95% in 2022 and then plummeted by 115.51% in 2024.
- Quarterly analysis of 5 years shows Ocular Therapeutix's Income towards Parent Company stood at -$19.7 million in 2021, then fell by 5.38% to -$20.8 million in 2022, then decreased by 9.42% to -$22.7 million in 2023, then tumbled by 115.51% to -$49.0 million in 2024, then tumbled by 56.01% to -$68.0 million in 2025.
- Its last three reported values are -$68.0 million in Q3 2025, -$67.2 million for Q2 2025, and -$63.1 million during Q1 2025.